Achieving Appropriate Access for the Treatment of Atopic Dermatitis: Medical and Pharmacy Management Strategies for Managed Care and Payer Professionals
Reserve your spot today for these upcoming webcasts!


Jointly provided by Postgraduate Institute for Medicine, the National Eczema Association and Impact Education, LLC.
Postgraduate Institute for Medicine     National Eczema Association     Impact Education, LLC
This activity is supported by independent educational grants from Sanofi Genzyme and Regeneron Pharmaceuticals, Pfizer, Inc. and Incyte Corporation.

2 Chances to Attend!

DateTimeRegister
Monday, May 16, 2022 1:30pm – 3:00pm ET Webcast Complete!
Thursday, June 2, 2022 12:30pm – 2:00pm ET Click here to reserve your spot

  Learn About
  • The clinical, economic, and humanistic burden of AD
  • Data from recently approved and emerging AD therapies
  • Benefits of multidisciplinary care in AD patients
  Expert Faculty Presenters
Edmund Pezalla, MD, PhD, MPH (June 2 only)
CEO
Enlightenment Bioconsult, LLC
Michele Guadalupe, MPH
Associate Director, Advocacy & Access
National Eczema Association
Peter Lio, MD
Clinical Assistant Professor of Dermatology and Pediatrics
Northwestern University Feinberg School of Medicine
Founding Director
Chicago Integrative Eczema Center
Michael Zeglinski, RPh (May 16 only)
Former SVP & CEO
Optum Specialty & Infusion Pharmacies
Terry Richardson, PharmD, BCACP
(June 2 only)
Vice President, Education Strategy and Development
Impact Education, LLC
  Who Should Attend?

The primary target audience for this initiative consists of medical directors, registered nurses, pharmacy directors, clinical pharmacists, specialty pharmacists, quality directors, as well as network physicians affiliated with various MCOs, health systems, and other payer organizations.

  Statement of Need/Program Overview

Novel treatments and management strategies have the potential to target the underlying pathology resulting in decreased clinical and economic burden for the patient and health care system. However, managed care pharmacists and other payer professionals can lack knowledge of the clinical, economic, and humanistic burden of atopic dermatitis (AD) which can empower them to enact health care benefit policy strategies to reduce the disease burden and enhance the potential for optimal treatment outcomes.

  Educational Objectives

At the conclusion of this activity, participants should be able to demonstrate improved ability to:
  • Explore the spectrum of clinical, economic, and humanistic burden of AD
  • Review clinical data from recently approved and emerging AD therapies
  • Evaluate benefit design strategies that can contribute to appropriate access and utilization, while simultaneously managing costs and improving treatment outcomes
  • Assess the benefits of multidisciplinary care in AD patients
  Agenda
Opening Comments
Michael Zeglinski, RPh (May 16 webcast)
Terry Richardson, PharmD, BCACP (June 2 webcast)
Clinical Update on the Evolving AD Treatment Paradigm
Peter Lio, MD
Evidenced-based Decision Making in a Cost Conscience Environment
Michael Zeglinski, RPh (May 16 webcast)
Edmund Pezalla, MD, PhD, MPH (June 2 webcast)
Medical and Pharmacy Management Strategies to Enhance AD Patient Outcomes (case-based discussion)
Terry Richardson, PharmD, BCACP
Audience Q&A Session
Key Takeaways and Closing Comments
  Accreditation Information
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine, Impact Education, LLC and the National Eczema Association. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education.

Universal Activity Number: JA4008162-9999-22-181-L01-P
Type of Activity: Knowledge

Please note: Pharmacists have up to 30 days to complete the evaluation and claim credit for participation so that information can be submitted to CPE Monitor as required.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. The existence or absence of COI for everyone in a position to control content will be disclosed to participants prior to the start of each activity.

Hardware/Software Requirements
Compatible with Internet Explorer 6 and up, Mozilla Firefox 3 and up, Safari 4.0, and Google Chrome 10 and up.

Fee Information
No additional fee is required to attend this CPE/CME activity.

If you have any questions, please call (215) 619-8812 or email info@impactedu.net.